Doug Dellinger, CEO and Co-FounderFor more than four decades, Doug Dellinger and Marvin Caruthers pursued one of nucleic acid chemistry’s most difficult problems: how to synthesize RNA reliably, at length, and without compromise. Their collaboration began long before RNA became commercially urgent and was grounded in Caruthers’ invention of phosphoramidite chemistry, the foundation of modern DNA and RNA synthesis.
Over years of incremental advances across the field, most new approaches improved one dimension of RNA synthesis while sacrificing another, such as length, purity, manufacturability, or scalability. Dellinger and Caruthers chose a different path. Rather than optimizing within those constraints, they set out to eliminate them. When their redesigned chemistry was published in 2011, it marked the first time they believed the core mechanistic barriers to practical RNA synthesis had been fully resolved. The result was a manufacturable process capable of delivering length, efficiency, and quality simultaneously.
A Mechanistic Redesign of RNA Synthesis
How did Cirena redesign protection of the 2′ hydroxyl to improve coupling efficiency?
RNA synthesis is inherently more complicated than DNA synthesis due to the presence of an extra reactive group, the 2′ hydroxyl, that when protected can impede efficient chain extension. This additional hydroxyl also reduces the pH range where RNA remains stable compared to DNA, limiting the chemical methods available for removing the 2'-hydroxyl protective group. Conventional strategies rely on protection techniques that add steps and complexity, often leading to lower coupling efficiency and reduced compatibility with chemical modifications used in RNA therapeutics.
Cirena approached the problem differently by redesigning how this position is protected and how neighboring chemical effects influence the reaction. The resulting system enables coupling efficiencies of approximately 99.8 percent per step, compared with roughly 98 percent for conventional approaches. Over long sequences, that difference compounds dramatically, allowing Cirena to produce RNAs that quickly become impractical under legacy methods.
The effect is visible even before purification.
“For a 100-nucleotide RNA, conventional synthesis often yields crude material containing only 20 to 25 percent of the correct sequence, while our crude output typically approaches 80 percent full-length product,” says Doug Dellinger, CEO and co-founder.
Instead of attempting to isolate a small usable fraction from predominantly unwanted material, Cirena’s purification process removes a relatively small proportion of impurities. This enables more selective purification while maintaining strong yields.
On the same industry-standard synthesis scale, Cirena reports generating up to ten times more usable RNA than conventional workflows. That margin allows the company to discard borderline fractions that others might retain, improving final product consistency while maintaining supply efficiency.
The stability of the chemistry also enables Cirena to support projects from early research quantities through therapeutic-scale manufacturing without major process redesign, helping customers move from discovery to scale-up with fewer technical transitions.
-
For a 100-nucleotide RNA, conventional synthesis often yields crude material containing only 20 to 25 percent of the correct sequence, while our crude output typically approaches 80 percent full-length product.
The stability of the chemistry also enables Cirena to support projects from early research quantities through therapeutic-scale manufacturing without major process redesign, helping customers move from discovery to scale-up with fewer technical transitions.
Synthesis, Purification, and Characterization
How does Cirena integrate synthesis, purification, and analytics to validate long RNA molecules?
Cirena’s platform controls the full lifecycle of long RNA production.
The company has developed proprietary affinity-based purification techniques designed specifically for long RNA molecules that standard chromatographic approaches struggle to separate. In parallel, Cirena has invested heavily in analytical workflows, including mass spectrometry methods refined over years to accurately measure and verify long RNAs.
This integrated approach allows Cirena to deliver RNA that is chemically defined, quantitatively measured, and analytically characterized, rather than relying on inferred composition or bulk UV estimates.
The company’s chemistry supported 100-nucleotide single-guide RNAs early in the CRISPR era and now enables researchers working on base editing, prime editing, and other advanced systems that require RNAs beyond 150 nucleotides. It has synthesized RNAs approaching 300 nucleotides for active customer programs.
These capabilities also extend to noncoding and regulatory RNAs, where functional regions commonly span 150 to 400 nucleotides and require precise chemical modification. By relying on chemical synthesis rather than transcription, Cirena enables customers to control both sequence architecture and modification placement, capabilities that are increasingly important as RNA molecules transition from research tools to therapeutic candidates.
Positioning RNA as a Reliable Experimental Input
Why is chemically defined RNA critical for reliable gene-editing and therapeutic research programs?
Cirena works with academic laboratories, gene-editing and cell-engineering teams, and biotechnology companies developing RNA-based therapeutics. By combining mechanistically optimized chemistry, high crude purity, scalable synthesis, specialized purification, and rigorous analytical validation, Cirena aims to ensure that RNA enters experiments as a known and dependable component rather than a hidden source of variability.
For customers, that reliability translates into clearer experimental interpretation, more predictable development pathways, and fewer disruptions as programs advance toward scale and regulatory review. For Cirena, it reflects the original goal behind its technology: solving RNA synthesis at the chemical level so that researchers can focus on biology rather than material uncertainty.
Evaluating Advanced RNA Synthesis Solutions for Therapeutic Discovery
The expanding role of RNA in modern life science research has transformed how biotechnology and pharmaceutical organizations approach molecular design. RNA molecules now underpin gene editing systems, emerging therapeutic modalities and a growing class of regulatory molecules discovered across the transcriptome. Executives responsible for sourcing RNA synthesis solutions therefore face a problem that extends well beyond routine reagent procurement. The quality, length and chemical flexibility of synthesized RNA increasingly determine whether experimental programs produce reliable results or stall under the weight of ambiguous data.
Traditional chemical synthesis approaches were originally optimized for DNA. RNA, however, presents a fundamentally more difficult challenge because of the additional chemical functionality present on each nucleotide. That small structural difference complicates synthesis reactions, introduces side products and limits the length of sequences that can be produced with acceptable yield. For many suppliers, coupling efficiencies around ninety-eight percent per synthesis step have long been considered the practical ceiling. At modest lengths this limitation appears manageable. At longer lengths, small inefficiencies compound and the proportion of incomplete or incorrect sequences grows rapidly.
The limitations of these methods have become more visible as research programs move toward longer functional RNA constructs. Early RNA interference applications required short sequences. Modern applications such as CRISPR guide systems, base editing and prime editing demand significantly longer strands. Non-coding RNAs and regulatory RNA structures frequently extend well beyond the ranges historically achievable with conventional chemistries. A synthesis platform capable of producing longer molecules with dependable purity therefore becomes central to experimental design, not merely a convenience.
Purity itself remains an underappreciated determinant of experimental reliability. Many laboratories still rely on inexpensive preparations that contain substantial quantities of incomplete or incorrect sequences. Such materials can introduce variability that only becomes visible later in complex biological assays. Researchers may then invest substantial time and cost interpreting results that originate from poorly characterized inputs. A synthesis provider that can deliver well-defined material from the outset reduces downstream uncertainty and improves the interpretability of experimental outcomes.
The future direction of RNA research further amplifies these requirements. Increasing attention is being paid to long non-coding RNAs, circular RNAs and other regulatory molecules that influence cellular metabolism and disease pathways. Many of these structures fall into sequence ranges that were historically inaccessible through chemical synthesis. Organizations preparing for this wave of discovery must evaluate synthesis partners not simply on price but on their ability to deliver long, well-characterized RNA molecules that support therapeutic development.
Cirena emerges as a compelling choice for organizations working at the frontier of RNA biology. Its platform stems from decades of nucleic acid chemistry research and builds on innovations designed to improve synthesis efficiency and sequence length. The chemistry behind its process achieves substantially higher coupling efficiency than traditional methods, allowing the production of RNA sequences that extend far beyond typical limits.
Higher synthesis efficiency translates into dramatically improved crude purity, which simplifies downstream purification and enables the company to provide well-characterized material rather than minimally processed products. Cirena also developed proprietary purification and analytical methods that allow accurate characterization of long RNA molecules, ensuring that researchers know precisely what is present in each sample. For organizations pursuing advanced gene editing, regulatory RNA research or therapeutic development, Cirena represents a rigorous and dependable RNA synthesis partner.
...Read more
RNA Synthesis Solutions Info
Q1
What led to Cirena being recognized among top RNA synthesis solution providers?
Cirena has earned recognition in RNA Synthesis Solutions through its focus on solving one of the most persistent challenges in nucleic acid chemistry: reliable synthesis of long RNA. Its proprietary platform enables production of RNA sequences ranging from 100 to 300+ nucleotides with high purity and consistency, surpassing limitations of conventional methods. By delivering chemically defined RNA with strong sequence integrity and rapid turnaround, the company supports advanced research in gene editing and therapeutics, strengthening its position in RNA Synthesis Solutions.
Q2
How does Cirena differentiate its approach to RNA synthesis solutions?
A chemistry-first innovation strategy defines how Cirena delivers RNA Synthesis Solutions. Its platform uses proprietary nucleoside chemistry and optimized coupling efficiency to significantly improve crude product quality compared to traditional synthesis. This results in higher yields of full-length RNA and reduces downstream purification complexity. Combined with an affinity-based purification system and integrated analytical validation, Cirena ensures that its RNA Synthesis Solutions deliver both precision and reproducibility for demanding applications.
Q3
How does Cirena support customers in research and development workflows?
Support within Cirena’s RNA Synthesis Solutions is structured around speed, customization and technical clarity. The company offers flexible RNA modifications, scalable production volumes and streamlined ordering processes that simplify complex synthesis requirements. With turnaround times typically completed within about ten business days, researchers can move quickly from design to experimentation. This responsiveness ensures that RNA Synthesis Solutions remain aligned with fast-paced research timelines.
Q4
What value do Cirena’s RNA synthesis solutions bring to advanced research?
High-quality input materials are critical for reliable experimentation, and Cirena’s RNA Synthesis Solutions directly address this need. Its long and ultra-long RNA constructs support applications such as CRISPR gene editing, RNA replacement therapies and functional genomics. By eliminating the need for stitching shorter sequences or performing extensive purification, the company enables faster iteration cycles and more accurate results. These benefits enhance the overall efficiency and reliability of RNA Synthesis Solutions in cutting-edge research.
Q5
What role do expertise and technology play in Cirena’s platform?
Scientific leadership and patented technology form the backbone of Cirena’s RNA Synthesis Solutions. Developed from research at the University of Colorado Boulder, its platform reflects years of innovation in nucleic acid chemistry. The integration of synthesis, purification and analytical validation ensures that every RNA product is well-characterized and consistent. This combination of expertise and technology enables Cirena to deliver RNA Synthesis Solutions that meet the precision requirements of modern therapeutic development.
Q6
Why is Cirena relevant to current trends in RNA-based therapeutics?
The rapid growth of RNA therapeutics and gene editing technologies has increased demand for longer, more complex RNA constructs, and Cirena addresses this need through its RNA Synthesis Solutions. Its ability to produce high-purity long RNA at scale aligns with evolving requirements in CRISPR, oncology research and vaccine development. By reducing traditional bottlenecks and improving material reliability, the company plays a key role in advancing RNA-driven innovation.
